Gongwin Biopharm Holdings Co. Ltd. (6617.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Gongwin Biopharm Holdings Co. Ltd. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 32.04 m TWD | 36.45 m TWD |
| Gross profit | 8.68 m TWD | 26.09 m TWD |
| Operating income | -156.15 m TWD | -208.93 m TWD |
| EBIT | -87.55 m TWD | -115.71 m TWD |
| Net income | -82.55 m TWD | -114.13 m TWD |
| Diluted EPS – continuing operations | -0.65 TWD | -0.93 TWD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Gongwin Biopharm Holdings Co. Ltd.
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
More stocks
- Sam-A Aluminiu (006110.KS)
- SSAW Hotels & Resorts Group Co.Ltd. (301073.SZ)
- Gravity Co Ltd (GRVY)
- Equasens SA (EQS.PA)
- Guangdong Sanhe Pile Co Ltd (003037.SZ)
- Shenzhen King Brother Electronics Technology Co.Ltd. (301041.SZ)
- Elridge Energy Holdings Berhad (0318.KL)
- Hanssem (009240.KS)
- TEJON RANCH CO (TRC)
- Kamada (KMDA)
- Note AB (publ) (NOTE.ST)
- POET Technologies Inc (POET)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.